View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. 2/A 1083
  • 2 Csolnoky Ferenc Megyei Kórház I. Belgyógyászati Osztály Veszprém

Az 5-aminoszalicilsav- (5-ASA-) készítmények mind a mai napig a colitis ulcerosa terápiájának alapvető gyógyszereit jelentik. Számos orálisan adható 5-ASA-készítmény van forgalomban, beleértve az azo-kötést tartalmazó prodrugokat (például sulfalazin, olsalazin, balzalazid), valamint a mesalazin elnyújtott és kontrollált hatóanyag-kibocsátású kiszereléseit. Az orális terápia hatékonysága a beteg jó együttműködésén is múlik, amelynek gátat szabhat a naponta többször adott, nagyszámú tabletta bevétele. Ez a tényező a colitis ulcerosában szenvedő betegek terápiájának pontos betartásában jelentős akadályt képezhet. A közelmúltban egy új, naponta egyszer adandó, egyedülálló multimátrix mesalazinkészítmény és a szintén naponta egy alkalommal adható mesalazingranulátum hatékonynak bizonyult az enyhe-közepes súlyosságú colitis ulcerosa indukciós és fenntartó terápiájában. A mellékhatásprofil ugyanakkor nem különbözött a hagyományos mesalazinkészítményektől. A ritka adagolás a betegek jobb hosszú távú compliance-e által hozzájárulhat a betegek hatékonyabb kezeléséhez és várhatóan a colitis ulcerosával kapcsolatos colorectalis carcinoma rizikójának csökkentéséhez. A szerzők az alábbi közleményben összefoglalják az új, naponta egyszer adandó mesalazinkészítmények rövid és közepes távú hatékonyságával és biztonságosságával kapcsolatban elérhető irodalmi adatokat.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Lakatos, P. L., Fischer, S., Lakatos, L. és mtsai: Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take “toll”? World J. Gastroenterol., 2006, 12 , 1829–1840.

    Lakatos L. , 'Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take “toll”? ' (2006 ) 12 World J. Gastroenterol. : 1829 -1840.

    • Search Google Scholar
  • Lakatos, P. L.: Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J. Gastroenterol., 2006, 12 , 6102–6108.

    Lakatos P. L. , 'Recent trends in the epidemiology of inflammatory bowel diseases: up or down? ' (2006 ) 12 World J. Gastroenterol. : 6102 -6108.

    • Search Google Scholar
  • Travis, S. P. L., Stange, E. F., Lémann, M. és mtsai: European evidence-based consensus on the management of ulcerative colitis, current management. J. Crohn Colitis, 2008, 2 , 24–62.

    Lémann M. , 'European evidence-based consensus on the management of ulcerative colitis, current management ' (2008 ) 2 J. Crohn Colitis : 24 -62.

    • Search Google Scholar
  • Safdi, M., DeMicco, M., Sninsky, C. és mtsai: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol., 1997, 92 , 1867–187.

    Sninsky C. , 'A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis ' (1997 ) 92 Am. J. Gastroenterol. : 1867 -187.

    • Search Google Scholar
  • Sutherland, L., MacDonald, J. K.: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2006, 2 , CD000543.

    MacDonald J. K. , 'Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis ' (2006 ) 2 Cochrane Database Syst. Rev. : CD000543 -.

    • Search Google Scholar
  • Ransford, R. A., Langman, M. J.: Sulphasalazine and mesalazine, serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 2002, 51 , 536–539.

    Langman M. J. , 'Sulphasalazine and mesalazine, serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines ' (2002 ) 51 Gut : 536 -539.

    • Search Google Scholar
  • Desreumaux, P., Ghosh, S.: Review article, mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment. Pharmacol. Ther., 2006, 24 (Suppl. 1) , 2–9.

    Ghosh S. , 'Review article, mode of action and delivery of 5-aminosalicylic acid – new evidence ' (2006 ) 24 Aliment. Pharmacol. Ther. : 2 -9.

    • Search Google Scholar
  • McCormack, P. L., Robinson, D. M., Perry, C. M.: Delayed-release multi matrix system (MMXTM) mesalazine in ulcerative colitis. Drugs, 2007, 67 , 2635–2642.

    Perry C. M. , 'Delayed-release multi matrix system (MMXTM) mesalazine in ulcerative colitis ' (2007 ) 67 Drugs : 2635 -2642.

    • Search Google Scholar
  • Kane, S. V., Cohen, R. D., Aikens, J. E. és mtsa: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol., 2001, 96 , 2929–2933.

    Aikens J. E. , 'Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis ' (2001 ) 96 Am. J. Gastroenterol. : 2929 -2933.

    • Search Google Scholar
  • Cervený, P., Bortlík, M., Kubena, A. és mtsai: Nonadherence in inflammatory bowel disease, results of factor analysis. Inflamm. Bowel Dis., 2007, 13 , 1244–1249.

    Kubena A. , 'Nonadherence in inflammatory bowel disease, results of factor analysis ' (2007 ) 13 Inflamm. Bowel Dis. : 1244 -1249.

    • Search Google Scholar
  • Su, C., Lewis, J. D., Goldberg, B. és mtsai: A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis. Gastroenterology, 2007, 132 , 516–526.

    Goldberg B. , 'A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis ' (2007 ) 132 Gastroenterology : 516 -526.

    • Search Google Scholar
  • Prakash, A., Markham, A.: Oral delayed-release mesalazine, a review of its use in ulcerative colitis and Crohn’s disease. Drugs, 1999, 57 , 383–408.

    Markham A. , 'Oral delayed-release mesalazine, a review of its use in ulcerative colitis and Crohn’s disease ' (1999 ) 57 Drugs : 383 -408.

    • Search Google Scholar
  • Bantel, H., Berg, C., Vieth, M. és mtsai: Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol., 2000, 95 , 3452–3457.

    Vieth M. , 'Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis ' (2000 ) 95 Am. J. Gastroenterol. : 3452 -3457.

    • Search Google Scholar
  • Rousseaux, C., Lefebvre, B., Dubuquoy, L. és mtsai: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med., 2005, 201 , 1205–1215.

    Dubuquoy L. , 'Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma ' (2005 ) 201 J. Exp. Med. : 1205 -1215.

    • Search Google Scholar
  • Osawa, E., Nakajima, A., Wada, K. és mtsai: Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology, 2003, 124 , 361–367.

    Wada K. , 'Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice ' (2003 ) 124 Gastroenterology : 361 -367.

    • Search Google Scholar
  • Brunner, M., Assandri, R., Kletter, K. és mtsai: Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther., 2003, 17 , 395–402.

    Kletter K. , 'Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation ' (2003 ) 17 Aliment. Pharmacol. Ther. : 395 -402.

    • Search Google Scholar
  • Shire Pharmaceuticals, Inc., Lialda TM, prescribing information. Wayne, PA, Shire Pharmaceuticals, 2007.

  • Sandborn, W. J., Hanauer, S. B.: Systematic review, the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther., 2003, 17 , 29–42.

    Hanauer S. B. , 'Systematic review, the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis ' (2003 ) 17 Aliment. Pharmacol. Ther. : 29 -42.

    • Search Google Scholar
  • D’Haens, G., Hommes, D., Engels, L. és mtsai: Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis, a phase II, dose-ranging study. Aliment. Pharmacol. Ther., 2006, 24 , 1087–1097.

    Engels L. , 'Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis, a phase II, dose-ranging study ' (2006 ) 24 Aliment. Pharmacol. Ther. : 1087 -1097.

    • Search Google Scholar
  • Pierce, D., Martin, P., Kern, M. és mtsa: MMXTM mesalazine, a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut, 2007, 56 (Suppl. III) , A158.

    Kern M. , 'MMXTM mesalazine, a pharmacokinetic evaluation of dose proportionality and the effect of food ' (2007 ) 56 Gut : A158 -.

    • Search Google Scholar
  • Dilger, K., Baumgaertner, E., Thomann, P.: Once-daily oral mesalazine (1.5 g/day or 3.0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial. Gut, 2007, 56 (Suppl. III) , A150.

    Thomann P. , 'Once-daily oral mesalazine (1.5 g/day or 3.0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial ' (2007 ) 56 Gut : A150 -.

    • Search Google Scholar
  • Prantera, C., Viscido, A., Biancone, L. és mtsai: A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm. Bowel Dis., 2005, 11 , 421–427.

    Biancone L. , 'A new oral delivery system for 5-ASA: preliminary clinical findings for MMx ' (2005 ) 11 Inflamm. Bowel Dis. : 421 -427.

    • Search Google Scholar
  • Lichtenstein, G. R., Kamm, M. A., Boddu, P. és mtsai: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol., 2007, 5 , 95–102.

    Boddu P. , 'Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis ' (2007 ) 5 Clin. Gastroenterol. Hepatol. : 95 -102.

    • Search Google Scholar
  • Kamm, M. A., Sandborn, W. J., Gassull, M. és mtsai: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 2007, 132 , 66–75.

    Gassull M. , 'Once-daily, high-concentration MMX mesalamine in active ulcerative colitis ' (2007 ) 132 Gastroenterology : 66 -75.

    • Search Google Scholar
  • Sandborn, W. J., Kamm, M. A., Lichtenstein, G. R. és mtsai: MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis, a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther., 2007, 26 , 205–215.

    Lichtenstein G. R. , 'MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis, a combined analysis of two randomized, double-blind, placebo-controlled trials ' (2007 ) 26 Aliment. Pharmacol. Ther. : 205 -215.

    • Search Google Scholar
  • Schreiber, S., Karlstadt, R., Barrett, K. és mtsa: MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis, time to initial symptom resolution. Gut, 2007, 56 (Suppl. III) , A160.

    Barrett K. , 'MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis, time to initial symptom resolution ' (2007 ) 56 Gut : A160 -.

    • Search Google Scholar
  • Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J. és mtsai: MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis, efficacy and tolerability in specific patient subpopulations. Aliment. Pharmacol. Ther., 2008, 27 , 1094–1102.

    Sandborn W. J. , 'MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis, efficacy and tolerability in specific patient subpopulations ' (2008 ) 27 Aliment. Pharmacol. Ther. : 1094 -1102.

    • Search Google Scholar
  • Kruis, W., Gorelov, A., Kiudelis, G. és mtsai: Once daily dosing of 3 g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology, 2007, 132 (Suppl. S) , 898.

    Kiudelis G. , 'Once daily dosing of 3 g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis ' (2007 ) 132 Gastroenterology : 898 -.

    • Search Google Scholar
  • Kruis, W., Greinwald, R., Mueller, R.: Factors influencing therapeutic efficacy of mesalamine (Salofalk Granules) in active ulcerative colitis, a combined analysis from 3 pivotal controlled studies. Gut, 2007, 56 (Suppl. S) , A156.

    Mueller R. , 'Factors influencing therapeutic efficacy of mesalamine (Salofalk Granules) in active ulcerative colitis, a combined analysis from 3 pivotal controlled studies ' (2007 ) 56 Gut : A156 -.

    • Search Google Scholar
  • Kamm, M. A., Lichtenstein, G. R., Sandborn, W. J. és mtsai: Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 57 , 893–902.

    Sandborn W. J. , 'Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis ' (2008 ) 57 Gut : 893 -902.

    • Search Google Scholar
  • Kamm, M. A., Hanauer, S. B., Lichtenstein, G. R. és mtsai: MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis, outcome in patients treated over 14-16 months. Gastroenterology, 2007, 132 (Suppl. S) , T1297.

    Lichtenstein G. R. , 'MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis, outcome in patients treated over 14-16 months ' (2007 ) 132 Gastroenterology : T1297 -.

    • Search Google Scholar
  • The mesalamine Study Group: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis, a randomized placebo-controlled trial. Ann. Intern. Med., 1996, 124 , 204–211.

    'An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis, a randomized placebo-controlled trial ' (1996 ) 124 Ann. Intern. Med. : 204 -211.

    • Search Google Scholar
  • Lichtenstein, G. R., Diebold, R., Karlstadt, R. G. és mtsai: Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose 5-aminosalicylic acid formulation can maintain remission with once- or twice-daily MMX mesalamine. Gastroenterology, 2007, 132 (Suppl. S) , T1295.

    Karlstadt R. G. , 'Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose 5-aminosalicylic acid formulation can maintain remission with once- or twice-daily MMX mesalamine ' (2007 ) 132 Gastroenterology : T1295 -.

    • Search Google Scholar
  • Lichtenstein, G. R., Diebold, R., Karlstadt, R. G. és mtsai: The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to moderate ulcerative colitis. Gastroenterology, 2007, 132 (Suppl. S) , T1284.

    Karlstadt R. G. , 'The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to moderate ulcerative colitis ' (2007 ) 132 Gastroenterology : T1284 -.

    • Search Google Scholar
  • Kamm, M. A., Hanauer, S. B., Diebold, R. és mtsai: Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX mesalazine and subsequent long-term remission rates, results from three international combined acute and maintenace studies. Gut, 2007, 56 (Suppl. III) , A154.

    Diebold R. , 'Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX mesalazine and subsequent long-term remission rates, results from three international combined acute and maintenace studies ' (2007 ) 56 Gut : A154 -.

    • Search Google Scholar
  • Prantera, C., Kohn, A., Campieri, M. és mtsai: Once daily MMX 5-aminosalicylic acid versus twice-daily Asacol for the maintenance of remission of ulcerative colitis. Gastroenterology, 2008, 134 (Suppl. S) , T1136.

    Campieri M. , 'Once daily MMX 5-aminosalicylic acid versus twice-daily Asacol for the maintenance of remission of ulcerative colitis ' (2008 ) 134 Gastroenterology : T1136 -.

    • Search Google Scholar
  • Dignass, A., Vermeire, S., Adamek, H. és mtsai: Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis, results from a multinational randomised controlled trial. Gut, 2007, 56 , OP-G-378.

    Adamek H. , 'Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis, results from a multinational randomised controlled trial ' (2007 ) 56 Gut : OP-G-378 -.

    • Search Google Scholar
  • Kruis, W., Laimas, J., Pokrotnieks, J. és mtsai: Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis. A double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology, 2008, 134 (Suppl. S) , T1124.

    Pokrotnieks J. , 'Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis. A double-blind, double-dummy, randomized, controlled, dose-ranging study ' (2008 ) 134 Gastroenterology : T1124 -.

    • Search Google Scholar
  • Loftus, E. V.: Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroent. Clin. North Am., 2006, 35 , 517–531.

    Loftus E. V. , 'Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis ' (2006 ) 35 Gastroent. Clin. North Am. : 517 -531.

    • Search Google Scholar
  • Lakatos, L., Mester, G., Erdelyi, Z. és mtsai: Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis, results of a population-based study. Inflamm. Bowel Dis., 2006, 12 , 205–211.

    Erdelyi Z. , 'Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis, results of a population-based study ' (2006 ) 12 Inflamm. Bowel Dis. : 205 -211.

    • Search Google Scholar
  • Velayos, F. S., Terdiman, J. P., Walsh, J. M.: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk, a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol., 2005, 100 , 1345–1353.

    Walsh J. M. , 'Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk, a systematic review and metaanalysis of observational studies ' (2005 ) 100 Am. J. Gastroenterol. : 1345 -1353.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2020 0 1 21
Nov 2020 0 16 33
Dec 2020 0 0 12
Jan 2021 0 3 27
Feb 2021 0 1 18
Mar 2021 0 5 23
Apr 2021 0 1 11